A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 334 in Healthy Subjects and Migraine Patients

Trial Profile

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 334 in Healthy Subjects and Migraine Patients

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Erenumab (Primary) ; Erenumab (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Amgen
  • Most Recent Events

    • 24 Jul 2017 Results of this and other study (NCT01723514) published in the Clinical Pharmacology and Therapeutics Journal.
    • 21 Jun 2015 Results presented at the 57th Annual Scientific Meeting of the American Headache Society.
    • 12 May 2015 According to an Amgen media release, the results of this study will be presented at the 17th Congress of the International Headache Society in Spain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top